# 510(k) SUMMARY AS REQUIRED BY SECTION 807.92(C)

1. Date the summary was prepared: August 18, 2010

2. Submitter's name: Address:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641 00-86-20-8711-1274-8999 00-86-20-8711-1434

Phone: Fax:

# Name of contact person:

Howard Mann   
SHERBO ASSOCIATES   
1 Congressional Drive,   
Apt. C, Greenville, DE 19807   
Phone: 215-369-3785   
Fax: 215-369-5246   
Email: sheryl@sherboassociates

3. Name of the device Common or usual name:

Immunochromatographic test for the qualitative detection of:   
Buprenorphine   
Oxycodone   
Propoxyphene

Trade or Proprietary or model name:

<table><tr><td rowspan=1 colspan=1>Trade or Proprietary or model name</td><td rowspan=1 colspan=1>Model Number</td></tr><tr><td rowspan=1 colspan=1>1. Wondfo One Step Buprenorphine Urine Test Strip</td><td rowspan=1 colspan=1>W13-S</td></tr><tr><td rowspan=1 colspan=1>2. Wondfo One Step Oxycodone Urine Test Strip</td><td rowspan=1 colspan=1>W21-S</td></tr><tr><td rowspan=1 colspan=1>3. Wondfo One Step Propoxyphene Urine Test Strip</td><td rowspan=1 colspan=1>W57-S</td></tr></table>

Classification: All are Class I medical devices with the following various product codes with Code of Federal Regulation references:

<table><tr><td colspan="2">Product Code CFR #</td></tr><tr><td>DJG</td><td>21CFR 862.3650</td></tr><tr><td>DJG</td><td>21CFR 862.3650</td></tr><tr><td>JXN</td><td>21CFR 862.3700</td></tr></table>

4. The legally marketed device to which we are claiming equivalence [807.92(a)(3)]:

1. Acon Laboratories, Inc. Acon BUP One Step Buprenorphene Test Strip, K060466.   
2. Acon Laboratories, Inc. Acon OXY One Step Oxycodone Test Strlp, K033047   
3. Acon Laboratories, Inc. Acon PPX One Step Propoxyphene Test Strip, K040445

# 5. Description of the device:

Assay Principle: Immunochromatographic assay for drugs of abuse using a lateral flow, one step system for the qualitative detection of specificdrugs inhuman urine.Eachassayuses a monoclonal antibody-dye congugate from mouse against drug with gold chloride and fixed drug-protein conjugate and anti-mouse IgG polyclonal antibody in membrane.

6. Intended use of the device:

Wondfo One Step Buprenorphine Urine Test Strip, Wondfo One Step Oxycodone Urine Test Strip, and Wondfo One Step Propoxyphene Urine Test Strip are intended for the qualltative determination of Buprenorphine, Oxycodone, d-Propoxyphene at the specific cut-off concentration in human urine. They are intended for healthcare professionals in a central laboratory setting only and that it is not orusen point-of-care settings.

# 7. Comparison to the predicate device

A summary comparison of the features of the Wondfo One Step Buprenorphine Urine Test Strip, Wondfo One Step Oxycodone Urine Test Strip, Wondo One StepPropoxyphene UrieTest Strip and the predicate devicess provided in the Table 1.

Table 1: Features comparison of Wondfo assays and the predicate devices   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device.</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For the qualitative determination of buprenorphine,oxycodone, propoxyphene individual in human urine.</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Buprenorphine (buprenorphine)Oxycodone (oxycodone)Propoxyphene (propoxyphene)</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assays based on theprinciple of antigen antibody immunochemistry.</td></tr><tr><td rowspan=1 colspan=1>Type Of Test</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Immunoassay principles that rely on antigen-antibodyinteractions to indicate positive or negative result</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Human urine</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Buprenorphlne (buprenorphine):10ng/mlOxycodone (oxycodone): 100 ng/mlPropoxyphene (propoxyphene): 300 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Strip</td><td rowspan=1 colspan=1>Strlp, Device</td></tr></table>

# 8. Performance data

# 8.1 Accuracy

240 (eighty of each drug) clinical urine specimens were analyzed by GC-MS and by each corresponding Wondfo one step drug of abuse test. Each Wondfo test was read by three viewers. Samples were divided by concentration into four categories:less than half the cutoff, near cutoff negative, near cuof

positive, and high positive.

Sample description:Unalterd clnicalurine samples were evaluatedThe testing samples include a totl 80 samples (40 negative and 40 positive) for each drug. Originally 25 drug clinical samples of varying concentrations were from Cutoff Value section, 10 negative samples and additional 45 clinical samples were from Shenzhen Drug Addiction Recovery Center. All these samples concentration were confirmed by GC-MS. The concentrations of drug urine samples range from $\textless - 5 0 \%$ cutoff, $50 \%$ cutoff\~cutoff, Cutoff\~ $\mathbf { + 5 0 }$ %cutoff, $> + 5 0 \%$ cutoff.

Number of study sites: one Type of study site: Our internal facility Operator description: Our internal staff

The following results are tabulated from comparison studies:

# Buprenorphine Method Comparison Study Results

Viewer A:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

$\%$ agreement among positives is $90 \%$ $9 5 \%$ Confidence Interval $7 4 . 5 \% - 1 0 0 \%$ p $\%$ agreement among negatives Is $9 7 . 5 \%$ $1 9 5 \%$ Confidence Interval $8 2 . 0 \% - 1 0 0 \%$

Viewer B:   

<table><tr><td>Wondfo Result</td><td>Negative</td><td>Less than half the cutoff concentration by GC/MS analysis</td><td>Near Cutoff Negative (Between 50% below the cutoff and the cutoff</td><td>Near Cutoff Positive (Between the cutoff and 50% above the cutoff</td><td>High Positive (greater than 50% above the cutoff concentration)</td></tr><tr><td>Positive</td><td>0</td><td>0</td><td>concentration) 2</td><td>concentration) 16</td><td>20</td></tr><tr><td>Negative</td><td>10</td><td>10</td><td>18</td><td>4</td><td>0</td></tr></table>

% agreement among positives is 90% (95% Confidence Interval 74.5% - 100%) % agreement among negatives is 95% (95% Confidence Interval 79.5% - 100%)

Viewer C:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

$\%$ agreement among positives is $90 \%$ $1 9 5 \%$ Confidence Interval $7 4 . 5 \% - 1 0 0 \% )$ $\%$ agreement among negatives is $100 \%$ $1 9 5 \%$ Confidence Interval $8 4 . 5 \% - 1 0 0 \%$

Oxycodone Method Comparlson Study Results

Viewer A:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>.1</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr></table>

$\%$ agreement among positives is $9 5 \%$ $1 9 5 \%$ Confidence Interval $7 9 . 5 \% - 1 0 0 \% )$ $\%$ agreement among negatives is $9 7 . 5 \%$ $1 9 5 \%$ Confidence Interval $8 2 . 0 \% - 1 0 0 \%$

Viewer B:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

$\%$ agreement among positives is $9 2 . 5 \%$ $9 5 \%$ Confidence Interval $7 7 . 0 \% - 1 0 0 \% )$ $\%$ agreement among negatives is $9 5 \%$ $9 5 \%$ Confidence Interval $7 9 . 5 \% - 1 0 0 \%$

Viewer C:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

% agreement among positives is 90% (95% Confidence Interval 74.5% - 100%) % agreement among negatives is 100% (95% Confidence Interval 84.5% - 100%

# Propoxyphene Method Comparison Study Results

Viewer A:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above the.cutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

% agreement among positlves is 90% (95% Confidence Interval 74.5% - 100%)

$\%$ agreement among negatives is $95 \%$ $9 5 \%$ Confidence Interval 79.5% - 100%)   
Viewer B:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

$\%$ agreement among positives is $9 2 . 5 \%$ $9 5 \%$ Confidence Interval $7 7 . 0 \% - 1 0 0 \% )$ $\%$ agreement among negatives Is $9 7 . 5 \%$ $1 9 5 \%$ Confidence Interval $8 2 . 0 \% - 1 0 0 \%$

Viewer C:   

<table><tr><td rowspan=1 colspan=1>WondfoResult</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr></table>

$\%$ agreement among positives is $8 7 . 5 \%$ $9 5 \%$ Confidence Interval $7 2 . 0 \% - 1 0 0 \% )$ $\%$ agreement among negatives is $100 \%$ $1 9 5 \%$ Confidence Interval $8 4 . 5 \% - 1 0 0 \%$

# 8.2 Performance Characteristics and Other information

The performance characteristics of the Wondo One Step Buprenorphine Urine Test Strip, Wondfo One Step O rineTest Srp nd Wonne ep oohrieet tr wevr y cuto cyev uuu shelf life time when used according to the package inserts.

Guangzhou Wondfo Biotech Co., Ltd. c/o Mr. Howard Mann   
1 Congressional Drive, Apt. C   
Greenville, DE 19807

# AUG 2 5 2010

Re: k093175 Trade/Device Name: Wondfo One Step Bruprenorphine Urine Test Regulation Number: 21 CFR $\ S 8 6 2 . 3 6 5 0$ EMP Regulation Name: Opiate Test System Regulatory Class: Class II Product Code: DJG, JXN Dated: August 20, 2010 Received: August 24, 2010

Dear Mr. Mann:

We have reviewed your Section 5 10(k) premarket notification of intent to market the device . referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathbf { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97) For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Divison starke Surveillance t 017-760.o questins regarde reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/ca7b95952e7f10d2df6d375e751058cb60f15237f7f4d584dc782dead866a87a.jpg)

Courtny C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Device Name: Wondfo One Step Buprenorphine Urine Test Strip

Indication For Use: The Wondo One Step Buprenorphine Urine Test Strip is intended for the qualitative determination of buprenorphine in human urine at the cut-off concentration of $1 0 \ n \mathbf { g } / \mathbf { m } \ l$ .

T and is not for use in point-of-care settings. For in vitro diagnostic use.

T  t ul result, a more specific alternate chemical method is needed. Gas chromatography/mass spectrometry (GcMS) o Liquid chromatography/mass spectrometry (LC/MS) are the preferred confirmatory methods.

Prescription Use X And/Or (21 CFR Part 801 Subpart D)

# Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Nog Ohentemi

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

5101k) K093175

Device Name: Wondfo One Step Oxycodone Urine Test Strip

Inatnor e Won  ri or e ualativ e of oxycodone in human urine at the cut-off concentration of 100 ng/ml.

T y and is not for use in point-of-care settings. For in vitro diagnostic use.

Ty oviey ely uati oesa  houl result, a more speciic alternate hemical method is needed. Gas chroatography/mass spectrometry Gc/S) Liquid chromatography/mass spectrometry (LC/MS) are the preferred confirmatory methods.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Nong Wend

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K093175

Device Name: Wondfo One Step Propoxyphene Urine Test Strip

Indication For Use: The Wondfo One Step Propoxyphene Urine Test Strip is intended for the qualitative determination of propoxyphene in human urine at the cut-off concentration of $3 0 0 \ n { \mathfrak { g } }/ { \mathfrak { m } } |$ .

Ts  t and is not for use in point-of-care settings. For in vitro diagnostic use.

y vit sal houl resut, a more specific alternate chemical method is needed. Gas chromatography/mass spectrometry (Gc/S) o Liquid chromatography/mass spectrometry (LC/MS) are the preferred confirmatory methods.

# Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/00ca8252e356856fb4bfdea1e6eac50f37eb7f24a6ef05f3e749bc97e1d65423.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) k093175

Page 3 of3